AKRO | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.95%

1 Month

2.22%

3 Months

48.55%

6 Months

-0.11%

1 Year

-45.28%

2 Year

120.06%

Key data

Stock price

$27.16

P/E Ratio

0.00

DAY RANGE

$26.32 - N/A

EPS

$0.00

52 WEEK RANGE

$11.25 - $53.77

52 WEEK CHANGE

-$0.45

MARKET CAP

1.889 B

YIELD

N/A

SHARES OUTSTANDING

69.431 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/11/2024

BETA

1.50

PUBLIC FLOAT

AVERAGE 10 VOLUME

$470,347

AVERAGE 30 VOLUME

$476,720

Company detail

CEO:
Region: US
Website: https://www.akerotx.com/
Employees: 39
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

AKRO - Akero Therapeutics Inc